HomeCompareSPVM vs JNJ

SPVM vs JNJ: Dividend Comparison 2026

SPVM yields 2.03% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPVM wins by $2.6K in total portfolio value
10 years
SPVM
SPVM
● Live price
2.03%
Share price
$68.90
Annual div
$1.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.7K
Annual income
$231.20
Full SPVM calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — SPVM vs JNJ

📍 SPVM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPVMJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPVM + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPVM pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPVM
Annual income on $10K today (after 15% tax)
$172.37/yr
After 10yr DRIP, annual income (after tax)
$196.52/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $507.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPVM + JNJ for your $10,000?

SPVM: 50%JNJ: 50%
100% JNJ50/50100% SPVM
Portfolio after 10yr
$21.3K
Annual income
$529.49/yr
Blended yield
2.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SPVM
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPVM buys
0
JNJ buys
0
No recent congressional trades found for SPVM or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPVMJNJ
Forward yield2.03%3.36%
Annual dividend / share$1.40$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$22.7K$20.0K
Annual income after 10y$231.20$827.78
Total dividends collected$2.2K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPVM vs JNJ ($10,000, DRIP)

YearSPVM PortfolioSPVM Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,903$202.79$10,676$355.77+$227.00SPVM
2$11,873$206.63$11,407$389.39+$466.00SPVM
3$12,914$210.29$12,198$426.53+$716.00SPVM
4$14,032$213.77$13,056$467.62+$976.00SPVM
5$15,231$217.08$13,987$513.12+$1.2KSPVM
6$16,517$220.22$14,998$563.56+$1.5KSPVM
7$17,897$223.20$16,098$619.52+$1.8KSPVM
8$19,376$226.01$17,295$681.69+$2.1KSPVM
9$20,961$228.68$18,599$750.82+$2.4KSPVM
10$22,659$231.20$20,022$827.78+$2.6KSPVM

SPVM vs JNJ: Complete Analysis 2026

SPVMStock

The Invesco S&P 500 Value with Momentum ETF (Fund) is based on the S&P 500 High Momentum Value Index (Index). The Fund will invest at least 90% of its total assets in the component securities that comprise the Index. The Index is comprised of 100 securities in the S&P 500 Index having the highest “value scores” and “momentum scores,” calculated pursuant to the index methodology. Underlying Index constituents are weighted by their value scores; securities with higher value scores receive relatively greater weights. The Fund and the Index are rebalanced and reconstituted semi-annually.Financial Professionals - Log in to view the fund’s Factor DNATM chartSource: Axioma, Inc. Factor score methodologyAxioma is used to calculate the data that goes into the charts. We use Axioma's global short time horizon risk model.The current factor exposures of the ETF relative to its benchmark index are shown using the bars in the chart. Each factor's band indicates the +/- one standard deviation exposure of the fund to that factor over the past three years.The bar color is determined by comparing the number of standard deviations the current exposure is from the average three-year exposure. Higher exposures are a bright color, while lower exposures are a dark color.See notes below for factor definitions.Value: Book to price; Small size: Natural log of the total issuer market capitalization average over the last month. Companies with a smaller market cap receive a higher score; Profitability: considers return-on-equity, return-on-assets, cash-flow-to-assets, cash-flow-to-income, gross margin and sales-to-assets; Momentum: cumulative return over last 20 days; Low Volatility: square root of 60-day average of absolute return / cross sectional market volatility. Lower volatility stocks receive a higher score; Leverage: equal weight average of debt-to-assets and debt-to-equity; Growth: equal weight average of earnings growth rate and the sales growth rate; Dividend Yield: trailing 12-month dividend yield.

Full SPVM Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this SPVM vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPVM vs SCHDSPVM vs JEPISPVM vs OSPVM vs KOSPVM vs MAINSPVM vs ABBVSPVM vs MRKSPVM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.